Portfolio

Product: 5-ALA/Sonodynamic therapy
Approach: A drug-device combination that uses a sonodynamic therapy, where a drug, or sonosensitizer, selectively accumulates in cancer cells and is activated under low intensity ultrasound to selectively target and kill the tumor cells through an outpatient procedure that may be repeated, as needed, to treat the disease.
Strategic Area: Medical Device
Funding Impact: Part of seed round of funding to support first-in-human clinical trial of the company’s proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas

Product: Focused Ultrasound System
Approach: Enables precision medicine for brain tumors accomplished by transient and reversible opening the blood-brain barrier (BBB), which can improve patient outcomes by accelerating drug approvals, and enabling liquid biopsy (blood) tests, providing a real-time view of the disease biology.
Strategic Area: Medical Device
Funding Impact: Preclinical development of device to enable preclinical safety studies and planning for first human clinical studies

Product: EnTrega CNS Drug Delivery System
Approach: EnTrega is a novel system engineered by EnClear to deliver therapies into the cerebrospinal fluid (CSF), and via proprietary software, optimize therapeutic residence time and drug distribution, potentially improving outcomes in a variety of CNS diseases, including brain tumors. The system will feature non-invasive patient monitoring, machine learning-enhanced safety protocols, and automated CSF sampling. 
Strategic Area: Medical Device
Funding Impact: To support pre-clinical development of EnTrega.

Product: 3D-Predict™Glioma
Approach: 3D-Predict™ Glioma test accurately predicts responders and non-responders to standard of care treatments, and can help inform therapy selection in the clinic for glioblastoma (GBM) and other high-grade glioma patients.
Strategic Area: Precision Medicine 
Funding Impact: To support further commercialization and adoption of 3D-Predict™Glioma

Product: SurVaxM
Approach: A first-in-class immunotherapy that targets survivin, a cell-survival protein. SurVaxM stimulates a patients’ own immune response to control tumor growth and prevent future disease recurrence. SurVaxM is currently being evaluated as a potential treatment for newly diagnosed glioblastoma (GBM) in clinical trials, and may ultimately be tested for efficacy in other tumor types. 
Strategic Area: Immuno-Oncology
Funding Impact: To support an ongoing phase 2b clinical study of SurVaxM in patients with newly diagnosed GBM, as well as subsequent registration-related work to prepare the company for potential commercialization of this therapy. 

Product: KL-50
Approach: Developing novel agents that could benefit patients with temozolomide resistant, MGMT mutant GBM, and potential other tumor types
Strategic Area: DNA Damage Response
Funding Impact: Preclinical development of lead candidate KL-50 and additional analogs

Product: TSM1001
Approach: Telo Therapeutics is developing an orally bioavailable, highly CNS-penetrant lead small molecule that is well positioned to become a best in class inhibitor of XPO1, a clinically validated but under-exploited oncology target.
Strategic Area: Precision Oncology
Funding Impact: Supporting preclinical evaluation of XPO1 targeted therapies

Product: TGX-007
Approach: Trogenix is a University of Edinburgh spinout developing a differentiated gene therapy (TGX-007) designed to deliver personalized immunotherapy for GBM patients. This asset is the result of research by Steven Pollard, PhD, a world-renowned glioblastoma (GBM) and gene therapy expert. The Trogenix platform is expected to have broad applicability across oncology and regenerative medicine.
Strategic Area: Immunotherapy – Gene Therapy
Funding Impact: To support IND-enabling work in preparation for first in human studies